Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

@article{Proctor2014VismodegibAI,
  title={Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.},
  author={Amber E Proctor and Lisa A Thompson and Cindy L O'bryant},
  journal={The Annals of pharmacotherapy},
  year={2014},
  volume={48 1},
  pages={99-106}
}
OBJECTIVE To review vismodegib, the first Food and Drug Administration (FDA)-approved Hedgehog (Hh) signaling pathway inhibitor, in the treatment of advanced basal cell carcinoma (BCC). DATA SOURCES MEDLINE and PubMed were searched using the terms vismodegib, GDC-0449, RG3616, and basal cell carcinoma for relevant clinical trials through September 2013. The FDA Web site, the National Clinical Trials registry, and abstracts from the American Society of Clinical Oncology (ASCO) were also… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

NCCN clinical practice guidelines in oncology: basal cell and squamous cell skin cancers

  • SJ Miller, RC Grekin, KC Nelson
  • Version 2.2013. http://www.nccn.org/professionals…
  • 2013
Highly Influential
3 Excerpts

Inhibition of hedgehog pathway in advanced bases-cell carcinoma

  • DD Von Hoff, PM LoRusso, CM Rudin
  • N Engl J Med
  • 2009
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…